Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Contrast-enhanced ultrasound (CEUS) detects effects of vascular disrupting therapy in an experimental model of gastric cancer.

Lang SA, Moser C, Gehmert S, Pfister K, Hackl C, Schnitzbauer AA, Stroszczynski C, Schlitt HJ, Geissler EK, Jung EM.

Clin Hemorheol Microcirc. 2014;56(4):287-99. doi: 10.3233/CH-121658.

PMID:
23271198
2.

Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.

Seshadri M, Sacadura NT, Coulthard T.

Angiogenesis. 2011 Dec;14(4):491-501. doi: 10.1007/s10456-011-9233-1. Epub 2011 Sep 7.

3.

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.

Baguley BC, McKeage MJ.

Future Oncol. 2010 Oct;6(10):1537-43. doi: 10.2217/fon.10.122. Review.

PMID:
21062153
4.

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.

Milanović D, Braun F, Weber W, Grosu AL, Behe M, Niedermann G.

BMC Cancer. 2012 Jun 13;12:242. doi: 10.1186/1471-2407-12-242.

5.

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V.

Cancer Biol Ther. 2008 Sep;7(9):1377-85. Epub 2008 Sep 2.

PMID:
18708754
6.

Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS).

Paprottka PM, Roßpunt S, Ingrisch M, Cyran CC, Nikolaou K, Reiser MF, Mack B, Gires O, Clevert DA, Zengel P.

BMC Cancer. 2015 May 8;15:373. doi: 10.1186/s12885-015-1333-7.

7.

Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.

Tokuyama J, Kubota T, Saikawa Y, Yoshida M, Furukawa T, Otani Y, Kumai K, Kitajima M.

Anticancer Res. 2005 Jan-Feb;25(1A):17-22.

8.

Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.

Zhang C, Wu X, Zhang M, Zhu L, Zhao R, Xu D, Lin Z, Liang C, Chen T, Chen L, Ren Y, Zhang J, Qin N, Zhang X.

PLoS One. 2013 Jun 5;8(6):e65264. doi: 10.1371/journal.pone.0065264. Print 2013.

9.

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.

Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O.

Int J Cancer. 2007 Apr 15;120(8):1803-10.

10.

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.

Head M, Jameson MB.

Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214.

PMID:
20050824
11.
12.

[EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].

Zhang J, Ji J, Yuan F, Ma T, Ye ZB, Yu YY, Liu BY, Zhu ZG.

Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):85-9. Chinese.

PMID:
19538880
13.

Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.

Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, Imai K, Shinomura Y.

Cancer. 2011 Jul 15;117(14):3135-47. doi: 10.1002/cncr.25893. Epub 2011 Jan 24.

14.

Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts.

Wu H, Xin Y, Xiao Y, Zhao J.

Cancer Biother Radiopharm. 2012 Apr;27(3):204-9. doi: 10.1089/cbr.2011.1103. Epub 2012 Jan 27.

PMID:
22283637
15.

ASA404: update on drug development.

Rehman F, Rustin G.

Expert Opin Investig Drugs. 2008 Oct;17(10):1547-51. doi: 10.1517/13543784.17.10.1547 . Review.

PMID:
18808313
16.

Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts.

Wang JW, Zheng W, Liu JB, Chen Y, Cao LH, Luo RZ, Li AH, Zhou JH.

PLoS One. 2013;8(3):e58274. doi: 10.1371/journal.pone.0058274. Epub 2013 Mar 1.

17.

Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Baguley BC, Siemann DW.

Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Review.

18.

(-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.

Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH.

World J Gastroenterol. 2007 Feb 28;13(8):1162-9.

19.

TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.

Hantel C, Ozimek A, Lira R, Ragazzon B, Jäckel C, Frantsev R, Reincke M, Bertherat J, Mussack T, Beuschlein F.

Mol Cell Endocrinol. 2016 Mar 5;423:87-95. doi: 10.1016/j.mce.2015.12.009. Epub 2016 Jan 6.

PMID:
26768118
20.

Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF.

Zhang Y, Han J, Yang X, Shao C, Xu Z, Cheng R, Cai W, Ma J, Yang Z, Gao G.

Oncol Rep. 2011 Sep;26(3):681-6. doi: 10.3892/or.2011.1318. Epub 2011 May 25.

PMID:
21617872

Supplemental Content

Support Center